Renewed Hope

Where standard therapies fail, precision medicine offers hope for late stage cancer.

With each cancer patient responding differently to treatment therapy, Intermountain ICG100™ tests offers a unique process of analyzing the genetic makeup of each individual patient. A team of skilled specialists review each test with the objective of preparing the most effective customised, targeted treatment plan for each patient.

Why Intermountain ICG100™?

Personalised cancer treatment.


Personalised Testing
Offers a targeted cancer panel that detects 162 genomic alterations.

Expert recommendations
A molecular tumor board made up of a panel of expert scientists and physicians who recommend individual, effective treatment options.

Who is the test for?

For patients diagnosed with stage IV cancer. Method approved for late-stage cancer patients who have failed a traditional treatment method.

How long does it take to get the results?

More information for clinicians

SNPs Insertions Deletions Copy Number Alterations
Sensitivity 98.3% 100% 100% 95%
Specificity 93.8% 99.64% 98.94% 94.11%
Mean depth of coverage >300×
Turn-around time <14 days for molecular tumor board report

The ICG100™ tests 162 genes that are associated in cancer pathways.

ICG100™ Gene List
ABL1 CDKN2B KIT RAD50 PTCH2
ABL2 CEBPA KRAS RB1 CBL
AKT1 CSF1R MAP2K1 RET SETBP1
AKT3 CTNNB1 MAP2K2 RICTOR ZRSR2
ALK DDR2 MAPK1 RNF43 ASXL2
APC DNMT3A MCL1 ROS1 BCORL1
AR DPYD MDM2 RPTOR CSF3R
ARAF EGFR MET RUNX1 DNMT1
ASXL1 EMSY MLH1 SF3B1 EED
ATM ERBB2 (HER2) MPL SLCO1B1 ELANE
ATR ERBB3 MRE11A SMAD4 ETNK1
ATRX ERBB4 MSH2 SMARCB1 FAM5C
AURKA ERCC2 MSH6 SMO GATA1
AURKB ESR1 MTOR SRC GATA2
AXL ETV6 MUTYH SRSF2 HNRNPK
BCL2 EZH2 MYC STK11 KDM6A
BRAF FGFR1 MYD88 SYK LUC7L2
BRCA1 FGFR2 NBN TERT MLL
BRCA2 FGFR3 NF1 TET2 NSD1
BTK FGFR4 NFE2L2 TP53 PHF6
CALR FLT3 NOTCH1 TPMT PRPF40B
CCND1 GNA11 NPM1 TSC1 PRPF8
CCND2 GNAQ NRAS TSC2 RAD21
CCND3 GNAS NTRK1 U2AF1 SF1
CD274 H3F3A NTRK2 UGT1A1 SF3A1
CDK12 HNF1A NTRK3 VEGFA SMC1A
CDK2 HRAS PALB2 VHL SMC3
CDK4 IDH1 PARP1 WT1 STAG2
CDK5 IDH2 PARP2 BCOR SUZ12
CDK6 IGF1R PDGFRA PDGFRB U2AF2
CDK8 JAK2 PMS2 DDR1
CDK9 JAK3 PTEN FLT1
CDKN2A KDR PTPN11 JAK1

Concordance of clinical significant variant detected by external NGS reference laboratory with ICG100™ panel are available upon request.

Specifications

Intermountain Precision Genomics
Country USA
Number of Genes 162 genes
Technology Whole Exon Sequencing of 162 cancer related genes.
Methods ICG100-2.0™ (was NGS to identify individual mutations within a person’s cancer cells to identify specific DNA targets for personalised drug treatment.)

DNA sequencing for 162 cancer-related genes. Test detects all classes of genomic alteration:

  • Insertions and deletions (indels)
  • Structural variants
  • Copy number alterations
  • SNPs
Performance SNP Sensitivity 98.83%
Insertions Sensitivity 100.00%
Insertions Specificity 99.64%
Deletions Sensitivity 100.00%
Deletions Specificity 98.94%
Mean Depth of Coverage >300×
% of tests with actionable mutations detected >80%
No. of Regions Sequenced 1300
Molecular Tumor Board? Yes
Types of therapy reported Targeted therapies, immuno-therapies, clinical trials.
Application For patients diagnosed with late stage cancer. Method approved for late-stage cancer patients who have failed a traditional treatment method.
Lab accreditation CAP accredited
Follow-up recommendations With the Molecular Tumour Board review of patients, specific recommendations as to what drugs to use to target that specific mutations can be made. Including oral medications that don’t have all the side effects of traditional therapies.
Recent updates Intermountain healthcare leaders are seeing promising results from the more personalised treatments for late-stage cancer patients due to the advancements in genomics diagnostic technology.